Effects of Renal Disease upon Drug Disposition

References

• Reidenberg M. M. “Drug Metabolism in Uremia,”. Clin. Nephrol 1975; 4: 83
   PubMedGoogle Scholar
• Reidenberg M. M. “The Biotransformation of Drugs in Renal Failure,”. Am. J. Med. 1977; 62: 482
   PubMed Web of Science ®Google Scholar
• Fraser D. R., Kodicek E. “Unique Biosynthesis by Kidney of a Biologically Active Vitamin D Metabolite,”. Nature 1970; 228: 764
   PubMed Web of Science ®Google Scholar
• Letteri J. M., Mellk H., Louis S., Kutt H., Durante P., Glazko A. “Diphenylhydantoin Metabolism in Uremia,”. N. Engl. J. Med. 1971; 285: 648
   PubMed Web of Science ®Google Scholar
• Odar-Cederlöf I., Borgä O. “Kinetics of Diphenylhydantoin in Uraemic Patients: Consequences of Decreased Protein Binding,”. Eux. J. j. Clin. harmacol 1974; 7: 31
   PubMed Web of Science ®Google Scholar
• Odar-Cederlöf I. “Studies of the Plasma Protein Binding of Drugs in Patients with Renal Failure,”. Thesis, Karoltnska Institute Stockholm, Sweden 1975
   Google Scholar
• Reynolds F., Ziroyanis P. N., Jones N. F., Smith S. E. “Salivary Phenytoin Concentrations in Epilepsy and in Chronic Renal Failure,”. Lancet 1976; 2: 384
   PubMed Web of Science ®Google Scholar
• Lichter M., Black M., Arias J. M. “The Metabolism of Antipyrine in Patients with Chronic Renal Failure,”. J. Pharmacol. Exp. Ther 1973; 187: 612
   PubMed Web of Science ®Google Scholar
• Maddocks J. L., Wake C. J., Harber M. M. “The Plasma Half-Life of Antipyrine In Chronic Uraemic and Normal Subjects,”. Br. J. Clin. Pharmacol 1975; 2: 339
   PubMed Web of Science ®Google Scholar
• Reidenberg M. M., Lowenthal D. T., Briggs W., Gas-Paro M. “Pentobarbital Elimination in Patients with Poor Renal Function,”. Clin. Pharmacol. Ther 1976; 20: 67
   PubMed Web of Science ®Google Scholar
• Wilkinson G. R., Shand D. G. “A Physiologic Approach to Hepatic Drug Clearance,”. Clin. Pharmacol. Ther 1975; 18: 337
   Google Scholar
• Loub W. D., Wattenberg L. W., Davis D. W. “Aryl Hydrocarbon Hydroxylase Induction in Rat Tissues by Naturally Occurring Indoles of Cruciferous Plants,”. J. Natl. Cancer Inst 1975; 54: 985
   PubMed Web of Science ®Google Scholar
• “Environmental Chemicals and Nutrition: Relationship to Metabolism, Action, and Toxicity of Drugs,”. Proceedings of Fourth Deer Lodge Conference on Clinical Pharmacology, Clin. Pharmacol. Ther., In Press
   Google Scholar
• Lichter M., Black M., Arias J. M. “The Metabolism of Antipyrine in Patients with Chronic Renal Failure,”. J. Pharmacol. Exp. Ther 1973; 187: 612
   PubMed Web of Science ®Google Scholar
• Dundee J. W., Annis D. “Barbiturate Narcosis in Uremia,”. Br. J. Anaesth 1955; 27: 114
   PubMed Web of Science ®Google Scholar
• Leber H. W., Schutterle E. “Oxidative Drug Metabolism in Liver Microsomes from Uremic Rats,”. Kidney Int 1972; 2: 152
   PubMed Web of Science ®Google Scholar
• Reidenberg M. M. “The Binding of Drugs to Plasma Proteins from Patients with Poor Renal Function,”. Clin. Pharmacokinet 1976; 1: 121
   PubMedGoogle Scholar
• Reidenberg M. M. “The Binding of Drugs to Plasma Proteins and the Interpretation of Measurements of Plasma Concentrations of Drugs in Patients with Poor Renal Function,”. Am. J. Med. 1977; 62: 466
   PubMed Web of Science ®Google Scholar
• Sjöholm I., Kober A., Odar-Cederlöf I., Borgä O. “Protein Binding of Drugs in Uremia and Normal Serum: The Role of Endogenous Binding Inhibitors,”. Biochem. Pharmacol 1976; 25: 1205
   PubMed Web of Science ®Google Scholar
• Muller W., Wollert U. “Influence of pH on the Benzodiazepine-Human Serum Albumin Complex,”. Nauyiv-Schmiedeberg's Arch. Pharmacol 1974; 283: 67
   PubMed Web of Science ®Google Scholar
• Andreassen F., Jakobsen P. “Determination of Furosemide in Blood Plasma and Its Binding to Proteins in Normal Plasma and in Plasma from Patients with Acute Renal Failure,”. Acta Pharmacol. Toxicol 1974; 35: 49
   PubMedGoogle Scholar
• Dromgoole S. H. “The Effect of Hemodialysis on the Binding Capacity of Albumin,”. Clin. Chim. Acta 1973; 46: 469
   Web of Science ®Google Scholar
• Craig W., Wagnild J. “Correction of Protein Binding Defect in Uremic Sera by Charcoal Treatment,”. Clin. Res. 1974; 22: 316A
   Google Scholar
• Reidenberg M. M., Odar-Cederlöf I., Von Bahr C., Borgä O., Sjöqvist F. “Protein Binding of Diphenylhydantoin and Desmethylimipramine in Plasma from Patients with Poor Renal Function,”. N. Engl. J. Med. 1971; 285: 264
   PubMed Web of Science ®Google Scholar
• Shoeman D. W., Azarnoff D. L. “The Alterations of Plasma Proteins in Uremia as Reflected in Their Ability to Bind Digi-toxin and Diphenylhydantoin,”. Pharmacology 1972; 7: 169
   PubMed Web of Science ®Google Scholar
• Campion D. S. “Decreased Drug Binding by Serum Albumin during Renal Failure,”. Toxicol. Appl. Pharmacol 1973; 25: 391
   PubMed Web of Science ®Google Scholar
• Boobis S. W. “Alteration of Plasma Albumin in Relation to Decreased Drug Binding in Uremia,”. Clin. Pharmacol. Ther 1977; 22: 147
   PubMed Web of Science ®Google Scholar
• Drayer D. E. “Active Drug Metabolites and Renal Failure,”. Am. J. Med. 1977; 62: 486
   PubMed Web of Science ®Google Scholar
• Drayer D. E., Lowenthal D. T., Woosley R. L., Nies A. S., Schwartz A., Reidenberg M. M. “Cumulation of N-Acetyl-procainamide, an Active Metabolite of Procainamide, in Patients with Impaired Renal Function,”. Clin. Pharmacol. Ther 1977; 22: 63
   PubMed Web of Science ®Google Scholar
• Szeto H. H., Inturrisi C. E., Houde R., Saal S., Cheigh J., Reidenberg M. M. “Accumulation of Normeperidine, an Active Metabolite of Meperidine, in Patients with Renal Failure or Cancer,”. Ann. Intern. Med. 1977; 86: 738
   PubMed Web of Science ®Google Scholar
• Pierides A. M., Alvarez-Ude F., Kerr D. N. S., Skillen A. W. “Clofibrate-Induced Muscle Damage in Patients with Chronic Renal Failure,”. Lancet 1975; 2: 1279
   PubMed Web of Science ®Google Scholar
• Elion G. B., Yu T., Gutman A. B., Hitchings G. H. “Renal Clearance of Oxypurinol, the Chief Metabolite of Allopurinol,”. Am. J. Med. 1968; 45: 69
   PubMed Web of Science ®Google Scholar
• Adam W. R., Dawborn J. K. “Urinary Excretion and Plasma Levels of Sulphonamides in Patients with Renal Impairment,”. Aust Ann Med 1970; 19: 250
   PubMedGoogle Scholar
• Balasubramaniam K., Mawer G. E., Pohl J., Simons P. “Impairment of Cognitive Function Associated with Hydroxy-amylobarbitone Accumulation in Patients with Renal Insufficiency,”. Br J Pharmacol 1972; 45: 360
   PubMed Web of Science ®Google Scholar